Cite
HARVARD Citation
Sibille, A. et al. (2020). Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels. Acta oncologica. pp. 257-259. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sibille, A. et al. (2020). Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels. Acta oncologica. pp. 257-259. [Online].